NVAX תחזית צמיחת רווח נקי למניה לשנה הבאה Novavax

Is it worth investing in Novavax, Inc. (NVAX), given the acceleration of vaccine development through AI protein modeling? The GURU.Markets terminal displays a chart of the forward net income growth rate, where the current reading is -766.60. The business model is based on US R&D centers with outsourced manufacturing. Meanwhile, John Jacobs' management has successfully stabilized the company through licensing agreements, restoring market confidence.

This indicator measures the expected percentage difference between current and future net earnings per share, reflecting the market's implied rate of business expansion. The trend in consensus EPS forecasts for the coming year for Novavax, Inc. (NVAX) demonstrates the company's ability to monetize the transition to combination vaccines and new partnerships, determining the long-term sustainability of share prices amid the saturation of the monovalent vaccine market.